How to approach hypercalcaemia

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 13, Issue 3, 2013, Pages 287-290

  Crowley, Rachel ^a   Gittoes, Neil ^b  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM; CINACALCET; DENOSUMAB; PARATHYROID HORMONE; PHOSPHORUS; SERUM ALBUMIN; SODIUM CHLORIDE; STEROID; TUBERCULOSTATIC AGENT; VITAMIN D; BIOLOGICAL MARKER; PARATHYROID HORMONE RELATED PROTEIN;

ABDOMINAL PAIN; ALBUMIN BLOOD LEVEL; ANOREXIA; ARTICLE; CALCIUM BLOOD LEVEL; CELL MEMBRANE DEPOLARIZATION; COMORBIDITY; CONFUSION; CONSTIPATION; EMERGENCY CARE; FATIGUE; HEART PALPITATION; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; MYALGIA; NAUSEA AND VOMITING; OSTEOLYSIS; PAIN; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PHOSPHATE BLOOD LEVEL; PRIMARY HYPERPARATHYROIDISM; PROTEIN SECRETION; TERTIARY HYPERPARATHYROIDISM; THIRST; VITAMIN BLOOD LEVEL; BLOOD; DIFFERENTIAL DIAGNOSIS; HOSPITALIZATION; HYPERPARATHYROIDISM; MALIGNANCY; NEOPLASM; TREATMENT OUTCOME;

BISPHOSPHONATES; HYPERCALCAEMIA; HYPERPARATHYROIDISM; MALIGNANCY; VITAMIN D;

BIOLOGICAL MARKERS; CALCIUM; DIAGNOSIS, DIFFERENTIAL; DIPHOSPHONATES; HOSPITALIZATION; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM, PRIMARY; NEOPLASMS; PARATHYROID HORMONE; PARATHYROID HORMONE-RELATED PROTEIN; TREATMENT OUTCOME;

EID: 84884524602     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.13-3-287     Document Type: Article

References (14)

1. Favus MJ, Goltzman D. Regulation of calcium and magnesium. In: Rosen CJ (ed), Primer on the metabolic bone diseases and disorders of mineral metabolism. Washington DC: The American Society for Bone and Mineral Research, 2008:104-8.
2. Chen RA, Goodman WG. Role of the calcium-sensing receptor in parathyroid gland physiology. Am J Physiol Renal Physiol 2004;286:F1005-11.
3. Bustamante M, Hasler U, Leroy V et al. Calcium-sensing receptor attenuates AVP-induced aquaporin-2 expression via a calmodulin-dependent mechanism. J Am Soc Nephrol 2008;19:109-16.
4. Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 2005;352:373-9.
5. McCurdy MT, Shanholtz CB. Oncologic emergencies. Crit Care Med 2012;40:2212-22.
6. Davies JH, Shaw NJ. Investigation and management of hypercalcaemia in children. Arch Dis Child 2012;97:533-8.
7. Rejnmark L, Amstrup AK, Mollerup CL et al. Further insights into the pathogenesis of primary hyperparathyroidism: A nested case-control study. J Clin Endocrinol Metab 2013;98:87-96.
8. Khan AA. Medical management of primary hyperparathyroidism. J Clin Densitom 2013;16:60-3.
9. Guarnieri V, Canaff L, Yun FH et al. Calcium-sensing receptor (CASR) mutations in hypercalcemic states: studies from a single endocrine clinic over three years. J Clin Endocrinol Metab 95:1819-29.
10. Bilezikian JP, Khan AA, Potts JT Jr. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 2009;94:335-9.
11. LeGrand SB, Leskuski D, Zama I. Narrative review: furosemide for hypercalcemia: an unproven yet common practice. Ann Intern Med 2008;149:259-63.
12. Cooper MS. Disorders of calcium metabolism and parathyroid disease. Best Pract Res Clin Endocrinol Metab 2011;25:975-83.
13. Legrand SB. Modern management of malignant hypercalcemia. Am J Hosp Palliat Care 2011;28:515-7.
14. Brown-Glaberman U, Stopeck AT. Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors. Biologics 2012;6:89-99.